Amyloid PET imaging — the molecular imaging technique using radiolabeled tracers binding amyloid-beta plaques in the brain to provide in vivo visualization of Alzheimer's pathology — has transformed Alzheimer's diagnosis from a clinical syndrome diagnosis to a pathology-confirmed diagnosis, with the Alzheimer's Disease Diagnostic Market reflecting amyloid PET as the cornerstone of biomarker-based AD diagnostics.

FDA-approved amyloid PET tracers — florbetapir (Amyvid), florbetaben (Neuraceq), and flutemetamol (Vizamyl) providing the commercial radiopharmaceutical market for amyloid brain imaging — have enabled widespread clinical amyloid PET adoption following regulatory approval. The Alzheimer's Association and Society of Nuclear Medicine's appropriate use criteria for amyloid PET have established the clinical guidelines that nuclear medicine physicians and neurologists use to justify amyloid imaging in appropriate patients.

CMS coverage for amyloid PET — the Centers for Medicare and Medicaid Services' April 2023 decision to provide Medicare coverage for amyloid PET in patients enrolled in qualifying registries (IDEAS study, New IDEAS) — represented a critical coverage milestone that has progressively expanded to broader CMS coverage linked to the approval of amyloid-targeting therapies. Lecanemab (Leqembi) and donanemab FDA approvals have been accompanied by CMS coverage decisions requiring amyloid confirmation before treatment, directly driving amyloid PET demand.

Amyloid PET clinical utility for treatment eligibility — the requirement that FDA-approved amyloid-targeting therapies require confirmation of amyloid pathology before treatment initiation — has transformed amyloid PET from a primarily research tool toward a clinical necessity for patients being evaluated for these treatments. The linkage between amyloid-targeting therapy eligibility and amyloid PET or CSF biomarker confirmation creates the permanent clinical demand that drug approval has established.

Do you think the cost of amyloid PET imaging will eventually decrease sufficiently to enable population-level screening for preclinical Alzheimer's disease before symptoms develop?

FAQ

What is amyloid PET and what does it show? Amyloid PET uses radioactive tracers that bind to beta-amyloid plaques in the brain; PET scanning visualizes tracer distribution showing increased uptake in brain regions with high amyloid burden; a positive scan confirms presence of amyloid pathology consistent with Alzheimer's disease; negative scan makes Alzheimer's pathology unlikely; amyloid PET is used to confirm AD diagnosis in uncertain cases and to determine treatment eligibility for amyloid-targeting therapies.

What are the FDA-approved amyloid PET tracers? Three amyloid PET tracers have FDA approval: florbetapir (Amyvid, Eli Lilly), florbetaben (Neuraceq, Life Molecular Imaging), and flutemetamol (Vizamyl, GE Healthcare); all three are F-18-labeled tracers with two-hour half-life enabling central production and regional distribution; tracers are injected intravenously with PET scanning performed approximately fifty to ninety minutes later; visual read and quantitative analysis provide amyloid burden assessment.

#AlzheimersDiagnostic #AmyloidPET #AlzheimersImaging #ADdiagnosis #FlorbetapirAmyvid #AmyloidImagingAD